The present disclosure relates generally to packaging for gloves. More particularly, the present disclosure relates to packaging for gloves having a barrier for protecting the gloves from contamination from microorganisms and other undesirable materials or contaminants, and methods for making the packaging.
Gloves are widely used as a protective measure and have become mandatory in many industries and nearly all medical and surgical settings. In particular, disposable gloves are required as a means for protecting medical and surgical staff from coming into contact with bodily fluids during surgical procedures, medical examinations, laboratory testing and other medical procedures. Disposable gloves have traditionally been made of rubber materials such as latex, thermoplastic materials such as vinyl, and other natural and synthetic materials.
Many gloves are provided in packaging having a cavity for holding the gloves. The packaging includes an opening for removing the gloves from the packaging. The opening is typically revealed by removing a perforated portion of the packaging to access the gloves. Once the perforated portion of the packaging is removed to reveal the opening, the gloves are exposed to the ambient environment. As the ambient environment may contain microorganisms, pathogens, small airborne particles of dust and debris and other air contaminants, the gloves contained in the packaging may be exposed to undesirable materials or contaminants that may contaminate the gloves while they are in the packaging.
Thus, there exists a need for a glove packaging that includes a barrier to protect gloves contained within the glove packaging from microorganisms, airborne particles and other materials or contaminants that may contaminate the gloves prior to removal from the packaging. Preferably, the barrier can also destroy any microorganisms, pathogens or other materials or contaminants that come in contact with the barrier to further reduce the possibility of contamination.
According to one embodiment of the present concepts, a packaging for gloves comprises a container having a cavity for holding the gloves. The container includes an opening for removing the gloves from the container. The packaging also comprises a barrier including an antimicrobial material positioned to cover at least a portion of the opening of the container.
In another embodiment of the present concepts, a method for making a packaging for gloves comprises providing a container having a cavity for holding the gloves. The container includes an opening for removing the gloves from the container. The method further comprises providing at least a first barrier having an antimicrobial material and attaching the first barrier to the container such that the barrier at least partially covers a portion of the opening of the container.
In yet another embodiment of the present concepts, a container for holding a plurality of gloves comprises a body portion, an opening and an antimicrobial film covering the opening. The antimicrobial film includes an aperture to facilitate removal of the gloves from the opening of the container.
The above summary of the present concepts is not intended to represent each embodiment or every aspect of the present concepts. The detailed description and Figures will describe many of the embodiments and aspects of the present concepts.
The foregoing and other advantages of the invention will become apparent upon reading the following detailed description and upon reference to the drawings.
While the invention is susceptible to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and will be described in detail herein. It should be understood, however, that the invention is not intended to be limited to the particular forms disclosed. Rather, the invention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention.
The container 14 and removable segment 20 may be comprised of a variety of materials or combinations of materials, such as paper, plastic or fabric. The gloves 12 may include medical and/or surgical disposable gloves that are comprised of rubber materials such as latex, thermoplastic materials such as vinyl, and other natural and synthetic materials, such as nitrile, polyvinyl chloride, polyethylene, polyisoprene, neoprene, polychloriprene, etc. The gloves 12 may include other materials, such as antimicrobial coatings and/or coatings for protecting the skin that include aloe, chamomile, vitamin(s), or combinations thereof and other suitable ingredients that may provide skin care benefits, such as moisturizing and soothing dry, irritated skin. In addition to disposable gloves, it is contemplated that other types of gloves, i.e., non-medical or non-surgical gloves, could be used with the present concepts.
The packaging 10 may also comprise a barrier 22 that covers at least a portion of the opening 18 of the container 14. The barrier 22 may be a film, a piece of paper laminated with film or any type of flexible material that is suitable for providing or acting as a barrier. The barrier 22 inhibits or prevents microorganisms, pathogens, small airborne particles of dust and debris and other air contaminants from contacting and thus contaminating the gloves 12 prior to removal from the packaging 10. Thus, the barrier 22 helps to protect the gloves 12 from being exposed to undesirable materials or contaminants while the gloves 12 are in the packaging 10. Providing gloves 12 that are free from undesirable materials or contaminants reduces the risk that patients and healthcare workers will be exposed to such materials or contaminants and thereby reduces the opportunity to spread potentially harmful and infectious materials or contaminants. Furthermore, providing gloves 12 that are free from undesirable materials or contaminants also reduces or prevents cross-contamination that may occur between different patients.
In one embodiment, where the barrier 22 is a film, the film is a thin sheet of material, such as polypropylene, polystyrene, polyester, polyamide, polyvinylchloride, polyethylene (low density polyethylene, medium density polyethylene and/or high density polyethylene), polyvinylidene chloride, regenerated cellulose, cellulose acetate, and/or combinations thereof. The film material selected may be based on factors such as cost, shelf-life, barrier effectiveness, performance, etc. The film, including the paper-laminated film and any of the embodiments described herein, may have a thickness of less than about 10 mils, particularly from about 1 mil to about 6 mils. The thickness may be selected based on a variety of factors such as barrier effectiveness, cost, material(s) used, performance characteristics such as transparency and flexibility, etc. The film may be clear or colored. The film may also be printed or plain, and may be flat, patterned or embossed. Also, the film may be laminated with one or more other materials, in addition to paper, such as foil, vinyl or other materials. The film, including the paper-laminated film and any of the embodiments described herein, helps to prevent exposure of the inside of the container 14 to microorganisms, airborne particles and other materials or contaminants.
The barrier 22 may be a single sheet of film or may be multi-layered, as shown in
As shown in the embodiment of
Thus, one method for making the packaging 10 for gloves 12 includes providing a container 14 having a cavity 16 for holding the gloves 12 and an opening 18 for removing the gloves 12 from the container 14. Once a barrier, such as barrier 22, 22a, 22b, is provided which includes the antimicrobial material, a suitable method for attaching the barrier 22, 22a, 22b can be used to cover at least a portion of the opening 18 of the container 14. In some embodiments, the barrier 22, 22a, 22b includes overlapping films or barriers that cover the opening 18 of the container 14 and form the slit 24 for removal of the gloves 12 from the container 14.
In the embodiments shown in
The barrier 22, 22a, 22b of the embodiments described herein may include an antimicrobial material(s). The antimicrobial material(s) may include, but is/are not limited to, silver-based antimicrobial materials, copper-based antimicrobial materials, chlorhexidene gluconate, benzalkonium chloride, monoquaternary and polyquaternary ammonium salt-based antimicrobial materials (including covalent bonded quaternary ammonium salt (QAS)), biguanide-based antimicrobials such as polyhexamethylene biguanide (PHMB), triclosan, zinc pyrithione, isothiazolinone-based antimicrobials, 10,10′-oxybisphenoxarsine-based (OPBA) antimicrobials, peptide-based antimicrobials, natural antimicrobials such as hops extract, honey and chitosan-based antimicrobials, and any combinations thereof. The antimicrobial material may be selected based on a variety of factors, such as an efficacy requirement (percent of reduction), time to kill, antimicrobial spectrum, i.e., how broadly the antimicrobial material can kill bacteria, or other viruses, mold, fungi, etc. The amount of antimicrobial material used may depend on the specific antimicrobial material used, as different antimicrobial materials will require different levels for effectiveness. Thus, the amount of antimicrobial material needed will vary, but each antimicrobial material will have an antimicrobially effective level.
The antimicrobial material may be added to the barrier 22, 22a, 22b according to different methods that include, but are not limited to, spraying, coating, mixing with a polymer before extrusion, or other methods suitable to result in an application or addition of the antimicrobial material to the barrier 22, 22a, 22b. The particular method chosen may depend on the type of manufacturing process being used to make the barrier 22, 22a, 22b, the end use of the product, cost and other relevant factors. In some embodiments, spraying may be the most cost effective method. In other embodiments, the antimicrobial material may be added to the barrier 22, 22a, 22b by mixing the antimicrobial material with the barrier material before extrusion. Mixing may be advantageous as it does not require additional steps in the manufacturing process. All of these methods provide for the antimicrobial material to be included on the surface of the barrier 22, 22a, 22b, distributed within the barrier 22, 22a, 22b, or both.
As shown in
Thus, the antimicrobial material 30 that is added to the barrier 22, 22a, 22b destroys the microorganisms and pathogens that may come in contact with the barrier 22, 22a, 22b and thus reduces and/or eliminates the amount of microorganisms that may be deposited on the disposable gloves 12 housed within the container 14. The antimicrobial material 30 in combination with the barrier 22, 22a, 22b creates a contaminant-free zone on the packaging 10 that assists in reducing or eliminating patients and healthcare workers' exposure to potentially infectious and harmful microorganisms and contaminants. Additionally, the barrier 22, 22a, 22b prevents or reduces the occurrence of airborne particles and other materials or contaminants that may contaminate the gloves prior to removal from the packaging.
In accord with aspects of the disclosed concepts, the antimicrobial material 30 can be a selected blend of two or more additives which are shown to most effectively achieve a 4-log reduction (˜99.9%) of priority microorganisms and contaminants. The test inoculum with which the effectiveness of the antimicrobial material 30 is shown may comprise, singly or in any combination, Staphylococcus aureus (or “S. aureus”; a common cause of staph infection, skin infections, respiratory disease, and food poisoning), methicillin resistant Staphylococcus aureus (or “MRSA”), Klebsiella pneumonia (or “K. pneumonia”; a form of bacterial pneumonia), Escherichia coli (commonly abbreviated “E. coli”; a well-known cause of serious food poisoning), Pseudomonas aeruginosa (or “P. aeruginosa”; a surface-borne bacteria with potentially fatal symptoms), or Acinetobacter baumannii (or “A. baumannii”; an antibiotic-resistant pathogenic bacteria that causes pneumonia and potentially fatal infections), for example. The test procedure with which the effectiveness of the antimicrobial material 30 is shown may include International Organization for Standardization (ISO) standard 22196:2007, “Plastics-Measurement of Antibacterial Activity on Plastics Surfaces,” or ISO 22196:2011, “Measurement of antibacterial activity on plastics and other non-porous surfaces,” both of which are incorporated herein by reference in their entireties.
The “Value of Antimicrobial Activity” can be represented as:
R=[ log(B/C)]
where: R=value of antimicrobial activity; B=average of the number of viable cells of bacteria on the untreated test piece after 0 hours; and, C=average of the number of viable cells of bacteria on the antimicrobial test piece after 24 hours. R is commonly referred to as the “log reduction” of antimicrobial activity. It may be desirable, for some preferred embodiments, that the antimicrobial material 30 provide at least a 4-log reduction (i.e., less than approximately 0.1% survival rate) of all selected microorganisms and contaminants (e.g., those enumerated in the previous paragraph). By way of non-limiting example, some configurations may require the antimicrobial material 30 exhibit at least approximately a 4.9 log reduction of S. aureus, at least approximately a 4.9 log reduction of K. pneumonia, at least approximately a 6.0 log reduction of E. coli, and/or at least approximately a 5.2 log reduction of MRSA (e.g., as determined in accordance with ISO 22196:2007). For some configurations, the antimicrobial material 30 must exhibit at least approximately a 5.3 log reduction of MRSA, at least approximately a 5.1 log reduction of K. pneumonia, and/or at least approximately a 5.4 log reduction of E. coli (e.g., as determined in accordance with ISO 22196:2007). For some configurations, the antimicrobial material 30 must exhibit at least approximately a 5.6 log reduction of P. aeruginosa (e.g., as determined in accordance with ISO 22196:2007). Some configurations may require the antimicrobial material 30 exhibit at least approximately a 5.2 log reduction of A. baumannii (e.g., as determined in accordance with ISO 22196:2007).
According to some embodiments, the antimicrobial material 30 is a selected combination of zinc-based and silver-based materials which are proven, individually or in combination, to achieve the above-mentioned minimum 4-log reduction of microorganisms and contaminants. One preferred batch includes a mixture of a zinc-based antimicrobial compound, such as ULTRA-FRESH® KW-100 available from Thomson Research Associates, Inc., of Toronto, Ontario, Canada, at levels ranging from approximately 0.075% to 0.1% of the total material weight, and a silver-based antimicrobial compound, such as ULTRA-FRESH® SA-18 available from Thomson Research Associates, Inc., at levels ranging from approximately 0.1% to 0.5% of the total material weight. The silver-based antimicrobial compound may derive from the Silver Refractories chemical family, may have a specific gravity of approximately 2.7, may have a time-weighted average (TWA) of approximately 10 mg/m3, may have a short term exposure limit (STEL) of 15 mg/m3, and may comprise glass, oxide, and silver phosphate. In a similar regard, the zinc-based antimicrobial compound may derive from the Pyrithione chemical family, may have a specific gravity of approximately 1.8, may have a time-weighted average (TWA) of approximately 0.35 mg/m3, and may comprise Bis(1-hydroxy-2(1H)-pyridinethionato-O,S)—(T-4) zinc and 2-Pyridinol-1-oxide. Optionally, the selected materials may exhibit bactericide, fungicide and/or algaecide characteristics.
As indicated above, the barrier 22 may be attached to the container 14 via an adhesive material. The adhesive may be a thermoplastic pressure sensitive adhesive (PSA), a hot-melt-adhesive, a thermoset adhesives, or any other adhesive with sufficient bonding strength for the intended application. It is desirable, for at least some applications, to pre-treat the barrier 22 prior to or during the attachment process in order to improve bonding strength and, thus, minimize any inadvertent detachment of the barrier 22 from the container 14. Applications where the barrier 22 is a polymeric film, for example, may require the contact side of the barrier, or selected portions thereof, be corona treated (also known as “air plasma” treated) to impart changes to the properties of the contact surface and thereby increase the surface tension of the film. Alternative methods by which the surface tension of the barrier 22 may be increased include etching, priming, flame treatment, and ozone treatment. For some applications, the film surface tension (or “dyne level”) is increased to at least approximately 42 dynes or, in some embodiments at least approximately 48 dynes, to assist the barrier 22 in adhering to the glove box container 14. The surface tension may be measured in accordance with DIN ISO 8296 or American Society for Testing and Materials (ASTM) standard D2578-09, both of which are incorporated herein by reference in their entireties. It may be desirable, for some embodiments, that the barrier 22 exhibits a minimum peel-force strength of 166-218 N/m or, for some embodiments, at least approximately 192 N/m. For some embodiments, the barrier 22 exhibits an average maximum pull-off force of at least approximately 184 N/m or, for some embodiments, at least approximately 230 N/m or, for some embodiments, at least approximately 275 N/m.
The container 14 of the glove packaging 10 may take on various shapes, sizes, and features within the scope of this disclosure. As shown in
While the present invention has been described with reference to one or more particular embodiments, those skilled in the art will recognize that many changes may be made thereto without departing from the spirit and scope of the present invention. Each of these embodiments and obvious variations thereof is contemplated as falling within the spirit and scope of the invention, which is set forth in the following claims.
This application is a Continuation of U.S. patent application Ser. No. 14/829,884, filed on Aug. 19, 2015, now allowed, which is a Continuation of U.S. patent application Ser. No. 13/790,091, which was filed on Mar. 8, 2013, now issued as U.S. Pat. No. 9,139,355, which is a Continuation-in-Part of U.S. patent application Ser. No. 12/148,448, which was filed on Apr. 18, 2008, now abandoned, each of which are incorporated herein by reference in their respective entireties and for all purposes.
Number | Name | Date | Kind |
---|---|---|---|
3145840 | Wright | Aug 1964 | A |
3239097 | Bates | Mar 1966 | A |
3502244 | Irvin | Mar 1970 | A |
3784056 | Spruyt | Jan 1974 | A |
3979020 | Braber | Sep 1976 | A |
3997703 | Nakashio | Dec 1976 | A |
4574952 | Masui | Mar 1986 | A |
4675347 | Mochizuki | Jun 1987 | A |
4677697 | Hayes | Jul 1987 | A |
4735317 | Sussman | Apr 1988 | A |
4844293 | McLaughlin | Jul 1989 | A |
4863064 | Dailey, III | Sep 1989 | A |
4997105 | Fischer | Mar 1991 | A |
5044494 | Tamura | Sep 1991 | A |
5065863 | Moyet-Ortiz | Nov 1991 | A |
5357636 | Dresdner | Oct 1994 | A |
5379897 | Muckenfuhs | Jan 1995 | A |
5381914 | Koyama | Jan 1995 | A |
5415320 | North | May 1995 | A |
5501323 | Denesha | Mar 1996 | A |
5522506 | Roulin | Jun 1996 | A |
5542557 | Koyama | Aug 1996 | A |
5542566 | Glaug | Aug 1996 | A |
5816440 | Shields | Oct 1998 | A |
5921434 | Hollander | Jul 1999 | A |
6021919 | Kelly | Feb 2000 | A |
6021920 | Aldape | Feb 2000 | A |
6062421 | Marley | May 2000 | A |
6112936 | Arizmendi | Sep 2000 | A |
6239097 | Wilson | May 2001 | B1 |
6514306 | Rohrbach | Feb 2003 | B1 |
6543642 | Milliorn | Apr 2003 | B1 |
6592702 | Nickell | Jul 2003 | B2 |
6719991 | Darouiche | Apr 2004 | B2 |
6766919 | Huang | Jul 2004 | B2 |
6780383 | Ettlinger | Aug 2004 | B1 |
6782675 | Banks | Aug 2004 | B1 |
7063233 | Jordan | Jun 2006 | B2 |
7189686 | Burt | Mar 2007 | B2 |
7238403 | Koslow | Jul 2007 | B2 |
7275640 | Bourne | Oct 2007 | B2 |
7291370 | Gipson | Nov 2007 | B2 |
7699189 | Tramontina | Apr 2010 | B2 |
9139355 | Yao | Sep 2015 | B2 |
9771201 | Yao | Sep 2017 | B2 |
20020043537 | Serbiak | Apr 2002 | A1 |
20020051754 | Schroeder | May 2002 | A1 |
20020179627 | Huang | Dec 2002 | A1 |
20020197425 | Wolf | Dec 2002 | A1 |
20040028931 | Bletsos | Feb 2004 | A1 |
20040043167 | Holzem | Mar 2004 | A1 |
20040084378 | Koslow | May 2004 | A1 |
20040091678 | Jordon | May 2004 | A1 |
20040166094 | Darouiche | Aug 2004 | A1 |
20040166102 | Darouiche | Aug 2004 | A1 |
20040245269 | Grinberg | Dec 2004 | A1 |
20050058673 | Scholz | Mar 2005 | A1 |
20050101993 | Scalzo | May 2005 | A1 |
20050115197 | Meyers | Jun 2005 | A1 |
20050129937 | Patton | Jun 2005 | A1 |
20050150788 | Feusner | Jul 2005 | A1 |
20050186258 | Wang | Aug 2005 | A1 |
20060091034 | Scalzo | May 2006 | A1 |
20060091035 | Scalzo | May 2006 | A1 |
20060177489 | Massouda | Aug 2006 | A1 |
20060204452 | Velamakanni | Sep 2006 | A1 |
20060222845 | Deng | Oct 2006 | A1 |
20070034330 | Frisk | Feb 2007 | A1 |
20070131706 | Jordan | Jun 2007 | A1 |
20070144666 | Frisk | Jun 2007 | A1 |
20080054011 | Grimard | Mar 2008 | A1 |
20080280145 | Paschkowski | Nov 2008 | A1 |
20090130157 | Ylitalo | May 2009 | A1 |
Number | Date | Country |
---|---|---|
2721789 | Jan 2017 | CA |
2843728 | Oct 2017 | CA |
2280884 | May 2014 | EP |
3011982 | Apr 2016 | EP |
2774570 | May 2016 | EP |
2765093 | Dec 2016 | EP |
2005082142 | Sep 2005 | WO |
2007004562 | Jan 2007 | WO |
2007070573 | Jun 2007 | WO |
2008136721 | Nov 2008 | WO |
2009129182 | Oct 2009 | WO |
Entry |
---|
Extended European Search Report corresponding to co-pending European Patent Application Serial No. 14158296.5, European Patent Office, dated Jul. 4, 2014; (12 pages). |
Extended European Search Report for Application No. EP 15003537.6, dated Mar. 18, 2016 (10 pages). |
Extended European Search Report for Application No. EP 09731868.7, dated Feb. 27, 2012 (9 pages). |
Extended European Search Report for Application No. EP 14167274.1, dated Jul. 10, 2014 (4 pages). |
International Search Report corresponding to International Patent Application No. PCT/US2009/40370, U.S. Patent Office, dated May 14, 2009, 2 pages. |
Written Opinion corresponding to International Patent Application No. PCT/US2009/40370, U.S. Patent Office, dated May 14, 2009, 5 pages. |
Number | Date | Country | |
---|---|---|---|
20170349353 A1 | Dec 2017 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14829884 | Aug 2015 | US |
Child | 15667322 | US | |
Parent | 13790091 | Mar 2013 | US |
Child | 14829884 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12148448 | Apr 2008 | US |
Child | 13790091 | US |